Abstract: Rheumatic joint inflammation (RA) is an interminable systemic immune system illness embodying irritation and lasting harm of the joints. Early treatment in RA is essential as it can avert illness movement and irreversible harm of the joints. Successful analysis and treatment of the illness is a test because of its heterogeneity. The momentum demonstrative tests are not adequately precise to describe the malady at ahead of schedule stages. Accordingly, RA is commonly analyzed just once harm to the joints has as of now started, a period at which the window for ideal treatment may have been missed. Thus, there is an in number interest for novel serological biomarkers to enhance the early determination and successful stratification of this rich illness, so that the patient is given focused on and convenient treatment. Biomarkers can redo the administration of RA by empowering the early determination, appraisal and expectation of malady seriousness, choice of treatment, and observing of reaction to treatment. Hence a software system is developed to detect Rheumatic arthritis disease at early stages using biomarkers.
Keywords: Antibodies, synovitis, biomarkers, cytokines, genes, proteins.